UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549




FORM
8-K





CURRENT
REPORT


Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934




Date of
Report (Date of earliest event reported)October 22,
2008




Progenics
Pharmaceuticals, Inc.


(Exact
name of registrant as specified in its charter)




Delaware
            
            000-23143
            
            13-3379479(State
      or other jurisdiction
              of
      incorporation)
            
            (Commission
              File
      Number)
            
            (IRS
      Employer
              Identification
      No.)777 Old Saw Mill River
      Road, Tarrytown, New York
            
            10591(Address
      of principal executive offices)
            
            (Zip
      Code)Registrant's telephone number,
      including area code(914)
      789-2800




Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (seeGeneral
Instruction A.2. below):






oWritten communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




oSoliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
  oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))











Item
8.01. Other Events.





Wyeth Pharmaceuticals, a
division of Wyeth (NYSE: WYE), with which Progenics collaborates in the
development and commercialization of RELISTOR®, has informed Progenics that
global net sales of RELISTOR for the current year through September 30 were $2.9
million, of which $0.8 million were made in the third quarter ending September
30.
 
 On Wyeth’s third-quarter
earnings call this morning, Joseph M. Mahady, President of Wyeth
Pharmaceuticals, said, “We are just getting out of the blocks with RELISTOR, and
the subcu[taneous] product has been launched in the U.S., Canada, Venezuela and
Europe....”  In Europe, RELISTOR has been launched in the United
Kingdom, Germany, Ireland, Denmark, Sweden, Finland and the
Netherlands.
 
 In mid-August, Wyeth began
full promotion of RELISTOR under a program that includes sales detailing, the
offering of early experience trial kits and company-directed educational
programs designed to achieve appropriate awareness of this
product.
 
 RELISTOR is the first drug in
a novel class for a completely new therapeutic use – opioid-induced
constipation.  The approved indication for RELISTOR addresses the
needs of individuals with advanced illness receiving palliative
care.  Ongoing clinical studies have the goal of expanding the use of
RELISTOR in other patient settings.
 
 Distribution of
early-experience trials kits began in mid-August, and distribution is expected
to continue through this November.
 
 Wyeth has also informed
Progenics that the initial U.S. pipeline fill (wholesaler purchases) upon launch
was as expected, and since then wholesaler sales to pharmacies and institutions
have been increasing month over
month.





SIGNATURES






Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.






PROGENICS
PHARMACEUTICALS, INC.


By:/s/ ROBERT A.
MCKINNEY


Robert A. McKinney


Chief Financial Officer, Senior
Vice President,


Finance & Operations and
Treasurer






Date:  October 22,
2008